Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The company's marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn's disease. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Cranford, New Jersey.